Decreased ubiquinone availability and impaired mitochondrial cytochrome oxidase activity associated with statin treatment

Toxicology Mechanisms and Methods

Volumn 19, Issue 1, 2009, Pages 44-50

  Duncan, Andrew J ^a   Hargreaves, Iain P ^a,b   Damian, Maxwell S ^c   Land, John M ^a,b   Heales, Simon J R ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^c UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

Author keywords

Cytochrome oxidase; Electron transport chain; Statin; Ubiquinone

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; CYTOCHROME C OXIDASE; GOSERELIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; LACTATE DEHYDROGENASE; MEVINOLIN; MITOCHONDRIAL ENZYME; PREDNISOLONE; SIMVASTATIN; UBIQUINONE; WARFARIN;

ADULT; AGED; ARTICLE; ASTROCYTE; BIOAVAILABILITY; CASE REPORT; CELL CULTURE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG SOLUBILITY; DRUG WITHDRAWAL; ENZYME ACTIVITY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HUMAN CELL; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LUNG ASPERGILLOSIS; LUNG EMBOLISM; MALE; MITOCHONDRIAL RESPIRATION; MUSCLE BIOPSY; MUSCLE TOXICITY; MUSCLE WEAKNESS; MYOPATHY; POLYNEUROPATHY; PRIORITY JOURNAL; PROSTATE CANCER; RESPIRATORY CHAIN; RHABDOMYOLYSIS; SIDE EFFECT; SKELETAL MUSCLE; TISSUE LEVEL; TOXICITY;

AGED; ANIMALS; ASTROCYTES; CELLS, CULTURED; CYCLOSPORINE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ELECTRON TRANSPORT COMPLEX IV; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ITRACONAZOLE; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MUSCULAR DISEASES; RATS; RHABDOMYOLYSIS; SIMVASTATIN; UBIQUINONE;

EID: 57149086339     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.1080/15376510802305047     Document Type: Article

References (59)

1. Almeida, A., Moncada, S., and Bolanos, J. P. 2004. Nitric oxide switches on glycolysis through the AMP protein kinase and 6-phosphofructo-2-kinase pathway. Nat. Cell Biol. 6:45-51.
2. Arenas, J., Fernandez-Moreno, M. A., Molina, J. A., et al 2003. Myoglobinuria and COX deficiency in a patient taking cerivastatin and gemfibrozil. Neurology 60:124-132.
3. Arnadottir, M., Eriksson, L.-O., Thysell, H., and Karkas, J. D. 1993. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl- coemzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron 65:410-413.
4. Bolanos, J. P., Heales, S. J., and Clark, J. B. 1995. Effect of peroxynitrite on the mitochondrial respiratory chain: differential susceptibility of neurones and astrocytes in primary culture. J. Neurochem. 64:1965-1972.
5. Bruckert, E. 2002. New advances in lipid-modifying therapies for reducing cardiovascular risk. Cardiology 97:59-66.
6. Carvalho, A. A., Lima, U.W. P., and Valiente, R. A. 2004. Statin and fibrate associated myopathy. Arq. Neuropsiquiatr. 62:257-261.
7. Diaz, F., Thomas, C. K., Garcia, S., et al 2005. Mice lacking COX10 in skeletal muscle recapitulate the phenotype of progressive mitochondrial myopathies associated with cytochrome c oxidase deficiency. Hum. Mol. Genet. 14:2737-2748.
8. Dimitroulakos, J., and Yeger, H. 1996. HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P-glycoprotein-expressing cells. Nat. Med. 2:326-333.
9. 10 as an internal standard. Clin. Chem. 51:2380-2382.
10. Endo, A., Kuroda, M., and Tanzawa, K. 1976. Competittive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett. 72:323-326.
11. Ericsson, J., and Dallner, G. 1993. Distribution, biosynthesis, and function of mevalonate pathway lipids. Subcell. Biochem. 21:229-272.
12. Ernster, L., and Dallner, G. 1995. Biochemical, physiological and medical aspects of ubiquinone function. Biochim. Biophys. Acta 1271:195-204.
13. Ernster, L., and Forsmark-Andree, P. 1993. Ubiquinol: an endogenous antioxidant in aerobic organisms. Clin. Invest. 40:380-390.
14. Estornell, E., Fato, R., Castelluccio, C., et al 1992. Saturation kinetics of coenzyme Q in NADH and succinate oxidation in beef heart mitochondria. FEBS Lett. 311:107-109.
15. Farmer, J. A., and Torre-Amione, G. 2000. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf. 23:197-213.
16. Faust, J. R., Brown, M. S., and Goldstein, J. L. 1980. Synthesis of delta 2-isopentenyl tRNA from mevalonate in cultured human fibroblasts. 255:6546-6548.
17. Folkers, K., Langsjoen, P., Willis, R., et al 1990. Lovastatin decreases coenzyme Q levels in humans. Proc. Natl. Acad. Sci. USA 87:8931-8934.
18. Gegg, M. E., Beltran, B., Salas-Pino, S., et al 2003. Differential effect of nitric oxide on glutathione metabolism and mitochondrial function in astrocytes and neurones: implications for neuroprotection/neurodegeneration? J. Neurochem. 86:228-237.
19. Hamilton-Craig, I. 2001. Statin-associated myopathy. Med. J. Aust. 175:486-489.
20. Hargreaves, I. P., Duncan, A. J., Heales, S. J. R., et al 2005. The effect of HMG-CoA reductase inhibitors on Coenzyme Q10. Drug Saf. 28:659-676.
21. Heales, S. J. R., Bolanos, J. P., Brand, M. P., et al 1996a. Mitochondrial damage: an important feature in a number of inborn errors of metabolism. J. Inher. Metab. Dis. 19:140-142.
22. Heales, S. J. R., Hargreaves, I. P., Olpin, S. E., et al 1996b. Diagnosis of mitochondrial electron transport chain defects in small muscle biopsies. J. Inher. Metab. Dis. 19(Suppl 1):151.
23. Holtzman, C. W., Wiggins, B. S., and Spinler, S. A. 2006. Role of P-glycoprotein in statin drug interactions. Pharmacotherapy 26:1601-1607.
24. Huang, K. C., Chen, C. W., Chen, J. C., et al 2003. HMG-CoA reductase inhibitors inhibit inducible nitric oxide synthase gene expression in macrophages. J. Biomed. Sci. 10:396-405.
25. Ikeda, U., Shimpo, M., Ikeda, M., et al 2001. Lipophilic statins augment inducible nitric oxide synthase expression in cytokine-stimulated cardiac myocytes. J. Cardiovasc. Pharm. 38:69-77.
26. Jacobson, J., Duchen, M., Hothersall, J., et al 2005. Induction of mitochondrial oxidative stress in astrocytes by nitric oxide precedes disruption of energy metabolism. J. Neurochem. 95:388-395.
27. Keenan, J. M. 2003. Treatment of patients with lipid disorders in the primary care setting: new guidelines and their implications. South Med. J. 96:266-275.
28. Keilhoff, G., and Wolf, G. 1993. Comparison of double fluorescence staining and LDH-test for monitoring cell viability in vitro. Neuroreport 18:125-132.
29. 1 particle, and reconstitution of succinate-cytochrome c reductase. Methods Enzymol. 10:217-235.
30. Laaksonen, R., Ojala, J.-P., Tikkanen, M. J., et al 1994. Serum ubiquinone concentrations after short and long-term treatment with HMG-CoA reductase inhibitors. Eur. Clin. Pharmacol. 46:313-317.
31. Laufts, U., La Fata, V., Plutzky, J., et al 1998. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97:1129-1135.
32. Lemmi, C. A., Pelikan, P. C., Geesaman, B., et al 1990. Kinetics of cyclosporine A-induced inhibition of succinate-coenzyme Q dehydrogenase in rat renal cortical mitochondria. Biochem. Med. Metab. Biol. 43:214-225.
33. Malik, N. N. 2004. Over the counter statins. Lancet 364:411.
34. Maltese, W. A., and Aprille, J. R. 1985. Relation of mevalonate synthesis to mitochondrial ubiquinone content and respiratory function in cultured neuroblastoma cells. J. Biol. Chem. 260:11524-11529.
35. McKenney, J. M. 2003. Pharmacologic characteristics of statins. Clin. Cardiol. 26(Suppl 3):III32-III38.
36. Mortensen, A. J., Leth, A., Agner, E., et al 1997. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol. Aspects Med. 18S:137-144.
37. Neale, R., Reynolds, T.M., and Saweirs, W. 2004. Statin precipitated lactic acidosis. J. Clin. Pathol. 57:989-990.
38. Neuvonen, P. J., Kantola, T., and Kivisto, K. T. 1998. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin. Pharmacol. Ther. 63:332-341.
39. Ogasahara, S., Engel, A., Frens, D., et al 1989. Muscle coenzyme Q deficiency in familial mitochondrial encephalomyositis. Proc. Natl. Acad. Sci. USA 86:2379-2382.
40. Pahan, K., Sheikh, F. G., Namboodiri, A. M. S., et al 1997. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia and macrophages. J. Clin. Invest. 100;2971-2979.
41. Päivä, H., Thelen, K. M., Van Coster, R., et al 2005. High dose statins and skeletal muscle metabolism in humans: a randomized controlled trial. Clin. Pharm. Ther. 78:60-68.
42. Philips, P. S., Haas, R. H., Bannykh, S., et al 2002. Statin-associated myopathy with normal creatine kinase levels. Ann. Intern. Med. 137:581-585.
43. Ragan, C. I., Wilson, M. T., Darley-Usmar, V. M., et al 1987. Subfractionation of mitochondria and isolation of the proteins of oxidative phosphorylation. In Darley-Usmar, V.M., Rickwood, D., and Wilson, M. T. (Eds.), Mitochondria, a practical approach, IRL Press, London, pp. 79-112.
44. Rahman, S., Hargreaves, I., Clayton, P., et al 2001. Neonatal presentation of coenzyme Q10 deficiency. J. Pediatrics 139:456-458.
45. Rattan, R., Giri, S., Singh, A. K., et al 2003. Rho A negatively regulates cytokine-mediated inducible nitric oxide synthase expression in brain-derived transformed cell lines: negetive regulation of IKKα. Free Radic. Biol. Med. 9:1037-1050.
46. Schick, B. A., Laaksonen, R., Frohlich, J. J., Paiva, H., Lehtimaki, T., Humphries, K. H., et al 2007. Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin. Clin. Pharmacol. Ther. 81:650-653.
47. Schmitz, G., and Drobnik, W. 2003. Pharmacogenomics and pharmacogenetics of cholesterol-lowering therapy. Clin. Chem. Lab. Med. 41:581-589.
48. Selak, M. A., de Chadarevian, J. P., and Melvin, J. J. 2000. Mitochondrial activity in Pompe's disease. Pediatr. Neurol. 23:54-57.
49. Shepherd, J. A., and Garland, P. B. 1969. The kinetic properties of citrate synthase from rat liver mitochondria. Biochem. J. 114:597-610.
50. Stewart, V. C., Land, J. M., Clark, J. B., and Heales, S. J. 1998. Comparison of mitochondrial respiratory chain enzyme activities in rodent astrocytes and neurones and a human astrocytoma cell line. Neurosci. Lett. 247:201-203.
51. Stewart, V. C., Sharp, M. A., Clark, J. B., et al 2000. Astrocyte-derived nitric oxide causes both reversible and irreversible damage to the neuronal mitochondrial respiratory chain. J. Neurochem. 75:694-700.
52. Tabernero, A., Bolaños, J. P., and Medina, J. M. 1993. Lipogenesis from lactate in rat neurons and astrocytes in primary culture. Biochem. J. 294:635-638.
53. Tavintharan, S., Ong, C. N., Jeyaseelan, K., Sivakumar, M., Lim, S. C., and Sum, C. F. 2007. Reduced mitochondrial coenzyme Q10 levels in HepG2 cells treated with high dose simvastatin: A possible role in statin-induced hepatotoxicity? Toxicol. Appl. Pharmacol. 223:173-179.
54. Thompson, P. D., Clarkson, P., and Karas, R. H. 2003. Statin-associated myopathy. JAMA 289:1681-1690.
55. Vassault, A. 1983. L-Lactate dehydrogenase. UV method with pyruvate and NADH. In Bergmeyer, J., and Grassl, M. (Eds.), Methods of Enzymic Analysis, Vol 3, Verlag Chemie GmbH, Weinheim, pp. 118-126.
56. Wagner, B. K., Kitami, T., Gilbert, T. J., Peck, D., Ramanathan, A., Screiber, S. L., et al 2008. Large-scale chemical dissection of mitochondrial function. Nat. Biotechnol. 26:343-351.
57. Weber, W. 2001. Drug firm withdraws statins from the market. Lancet 358:568.
58. Wharton, D. C., and Tzagoloff, A. 1967. Cytochrome oxidase from beef heart mitochondria. Methods Enzymol. 10:245-250.
59. Willis, R. A., Folkers, K., Tucker, J. L., et al 1990. Lovastatin decreases coenzyme Q levels in rats. Proc. Natl. Acad. Sci. USA 87:8928-8930.